Ranexa Approval History
FDA Approved: Yes (First approved January 27, 2006)
Brand name: Ranexa
Generic name: ranolazine
Dosage form: Extended-Release Tablets
Company: CV Therapeutics, Inc.
Treatment for: Angina
Ranexa (ranolazine) is an antianginal and anti-ischemic agent indicated for the treatment of chronic angina.
Development History and FDA Approval Process for Ranexa
|Nov 6, 2008||FDA Approves Ranexa for First Line Anti Anginal Use|
|Dec 19, 2007||FDA Approves New Mechanism of Action Labeling for Ranexa|
|Aug 14, 2007||CV Therapeutics Launches 1000 mg Ranexa Tablet|
|Jan 27, 2006||Ranexa Approved - CV Therapeutics, Inc. - Treatment for Chronic Angina|
|Jul 27, 2005||CV Therapeutics Submits Amendment to Ranexa (ranolazine)|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.